Haemonetics Corporation (NYSE:HAE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Haemonetics Corporation (NYSE:HAE) have received an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $79.70.

Several brokerages have weighed in on HAE. Citigroup lowered their target price on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Raymond James Financial restated an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. Barrington Research lifted their price objective on Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, December 6th. Finally, BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research report on Friday, November 21st.

Haemonetics Trading Up 3.9%

Shares of HAE stock opened at $87.11 on Friday. The business’s fifty day moving average price is $64.00 and its 200 day moving average price is $64.19. The firm has a market capitalization of $4.08 billion, a PE ratio of 25.47, a P/E/G ratio of 1.58 and a beta of 0.30. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.64 and a quick ratio of 1.03. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same period in the previous year, the firm earned $1.12 EPS. The business’s revenue was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, sell-side analysts forecast that Haemonetics will post 4.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC raised its holdings in shares of Haemonetics by 372.8% in the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after acquiring an additional 1,678,630 shares during the last quarter. Millennium Management LLC raised its stake in Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after purchasing an additional 755,592 shares during the last quarter. Norges Bank purchased a new position in Haemonetics in the 2nd quarter valued at about $36,822,000. Invenomic Capital Management LP lifted its holdings in Haemonetics by 1,691.5% in the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after purchasing an additional 470,502 shares in the last quarter. Finally, SG Capital Management LLC boosted its stake in shares of Haemonetics by 92.5% during the 2nd quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock worth $67,663,000 after purchasing an additional 435,660 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.